Search

AZD3409

AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004.

Mesmulogene ancovacivec

with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in … Expression of IL-2 augments the specific CTL response against MUC1 expressing cells. [L5191]

Butyrylcholinesterase

Vapitadine

Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis … An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.

N-chlorotaurine

N-chlorotaurine is an inhibitor of inducible nitric oxide synthase and IkappaB kinase.

Bezitramide

After cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. Bezitramide has never been FDA approved and is currently a schedule II drug. … Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [A14383], and marketed under the name Burgodin.

Asvasiran

Asvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.

IRX-2

It is being investigated to promote or enhance an anti-cancer immune response.

MBX-2044

MBX-2044 was under investigation in clinical trial NCT00422487 (Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes).

Daxdilimab

Daxdilimab is under investigation in clinical trial NCT04526912 (Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection).